相似文献
1
Research Progress of Biliary Tract Cancers.
Cancers (Basel). 2021 Feb 22;13(4):919. doi: 10.3390/cancers13040919.
2
Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.
Dig Dis Sci. 2016 Dec;61(12):3627-3632. doi: 10.1007/s10620-016-4310-3. Epub 2016 Sep 21.
3
[Advance in immunotherapy on biliary tract cancers].
Zhonghua Wai Ke Za Zhi. 2021 Feb 1;59(2):156-160. doi: 10.3760/cma.j.cn112139-20200515-00382.
4
Immunotherapy of biliary tract cancer.
Tumour Biol. 2016 Mar;37(3):2817-21. doi: 10.1007/s13277-015-4743-x. Epub 2016 Jan 4.
5
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations.
Chin Clin Oncol. 2016 Oct;5(5):61. doi: 10.21037/cco.2016.10.09.
6
FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.
Oncotarget. 2016 Jun 7;7(23):34617-29. doi: 10.18632/oncotarget.8964.
7
Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
J Gastroenterol. 2017 Feb;52(2):218-228. doi: 10.1007/s00535-016-1230-0. Epub 2016 Jun 29.
8
Clinical and Translational Research Challenges in Biliary Tract Cancers.
Curr Med Chem. 2020;27(29):4756-4777. doi: 10.2174/0929867327666200123090153.
9
Surgical management of biliary tract cancers.
Chin Clin Oncol. 2016 Oct;5(5):63. doi: 10.21037/cco.2016.10.03.
10
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
BMC Cancer. 2020 Jul 23;20(1):688. doi: 10.1186/s12885-020-07185-6.
本文引用的文献
1
Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation.
Cancers (Basel). 2020 Oct 27;12(11):3157. doi: 10.3390/cancers12113157.
2
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.
Cancers (Basel). 2020 Oct 27;12(11):3149. doi: 10.3390/cancers12113149.
3
Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review.
Cancers (Basel). 2020 Sep 30;12(10):2817. doi: 10.3390/cancers12102817.
4
Prevention and treatment of FGFR inhibitor-associated toxicities.
Crit Rev Oncol Hematol. 2020 Nov;155:103091. doi: 10.1016/j.critrevonc.2020.103091. Epub 2020 Sep 1.
5
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.
Cancers (Basel). 2020 Sep 11;12(9):2599. doi: 10.3390/cancers12092599.
6
Role of Chemokines in the Biology of Cholangiocarcinoma.
Cancers (Basel). 2020 Aug 7;12(8):2215. doi: 10.3390/cancers12082215.
7
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.
Cancers (Basel). 2020 Aug 6;12(8):2190. doi: 10.3390/cancers12082190.
8
Examination of Prognostic Factors Affecting Long-Term Survival of Patients with Stage 3/4 Gallbladder Cancer without Distant Metastasis.
Cancers (Basel). 2020 Jul 27;12(8):2073. doi: 10.3390/cancers12082073.
9
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
Cancers (Basel). 2020 Jul 24;12(8):2039. doi: 10.3390/cancers12082039.
10
Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial.
Cancers (Basel). 2020 Jul 20;12(7):1975. doi: 10.3390/cancers12071975.
Zotero 插件